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Abstract
Data on genetic and environmental factors influencing PAI-1 levels and their consequent effect on clot lysis in black African
populations are limited. We identified polymorphisms in the promoter area of the PAI-1 gene and determined their
influence on PAI-1act levels and plasma clot lysis time (CLT). We also describe gene-environment interactions and the effect
of urbanisation. Data from 2010 apparently healthy urban and rural black participants from the South African arm of the
PURE study were cross-sectionally analysed. The 5G allele frequency of the 4G/5G polymorphism was 0.85. PAI-1act increased
across genotypes in the urban subgroup (p = 0.009) but not significantly in the rural subgroup, while CLT did not differ
across genotypes. Significant interaction terms were found between the 4G/5G polymorphism and BMI, waist circumference
and triglycerides in determining PAI-1act, and between the 4G/5G polymorphism and fibrinogen and fibrinogen gamma
prime in determining CLT. The C428T and G429A polymorphisms did not show direct relationships with PAI-1act or CLT but
they did influence the association of other environmental factors with PAI-1act and CLT. Several of these interactions differed
significantly between rural and urban subgroups, particularly in individuals harbouring the mutant alleles. In conclusion,
although the 4G/5G polymorphism significantly affected PAI-1act, it contributed less than 1% to the PAI-1act variance.
(Central) obesity was the biggest contributor to PAI-1act variance (12.5%). Urbanisation significantly influenced the effect of
the 4G/5G polymorphism on PAI-1act as well as gene-environment interactions for the C428T and G429A genotypes in
determining PAI-1act and CLT.
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Introduction
The prevalence of cardiovascular disease (CVD) has increased
significantly in developing countries, and will continue to do so in
the future [1]. The increase in morbidity and mortality from CVD
is also seen in the black population of South Africa [2,3],
particularly as a result of urbanisation, which is the change in
lifestyle patterns brought about by the on-going migration from
rural to urban settings. One of the factors that have repeatedly
been shown to be associated with an increased risk of CVD is
increased levels of plasminogen activator inhibitor type-1 (PAI-1)
[4,5]. PAI-1 can contribute to the development of CVD through
several mechanisms, including influencing plaque formation as
well as being a major inhibitor of blood clot lysis [6,7]. The speed
with which the body can lyse clots, often reported as lysis time, has
been linked to CVD [8]. This reflects an individual’s fibrinolytic
potential and can be measured with the use of global fibrinolytic
assays. PAI-1 antigen (PAI-1ag) levels have been found to explain a
large portion (24%) of the variance in clot lysis time (CLT) in a
white population [9], while PAI-1 activity (PAI-1act) explained
27% of CLT variance in the black African PURE population [10].
PAI-1 levels have previously been shown to be consistently
lower in black African and African American populations than in
populations of European decent [11–16]. However, as a result of
urbanisation and the increased prevalence of various CVD risk
factors associated with it, PAI-1 levels in urbanised black South
Africans are increasing [16,17]. Environmental factors known to
influence PAI-1 differ significantly between rural and urban
settings [17].
PAI-1 levels are influenced by both environmental and genetic
factors. There is, however, not much information available in the
literature regarding the genetic determinants of PAI-1 levels,
especially in black Africans. One of the most extensively studied
genetic polymorphisms known to influence PAI-1 levels is the 4G/
5G polymorphism [18,19]. This is a single base-pair insertion/
deletion polymorphism in the promoter area of the PAI-1 gene
[18,20]. The results of a recent large genome-wide association
study (GWAS) meta-analysis showed that a SNP (rs2227631),
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considered a proxy SNP for the 4G/5G polymorphism, was
strongly associated with PAI-1 levels [21]. High PAI-1 levels have
been found in participants who are homozygous for the 4G allele,
intermediate levels in heterozygous participants and low PAI-1
levels in 5G homozygotes [12,22,23]. The 4G/5G polymorphism
is, furthermore, considered to be a response polymorphism. This
implies that the difference in PAI-1 levels between 4G and 5G
becomes more obvious in the presence of disease and/or
environmental factors which stimulate PAI-1 expression [24]. A
limited number of studies in African Americans showed a higher
prevalence of the 5G allele than in whites [12,25]. Much less data
is available for continental African populations. To date, only
three small-scale studies have been performed in black African
individuals, showing an even higher prevalence of the 5G allele
than in African Americans [15,26,27].
The aim of this study was therefore to identify genetic
polymorphisms in the promoter area of the PAI-1 gene and to
determine their effect on PAI-1act. In addition we investigated
whether these possible differences in PAI-1act levels translated into
altered global fibrinolytic potential (plasma clot lysis time). Owing
to large differences in environmental factors between the rural and
urban setting, we also aimed to investigate the effect of gene-
environment interactions (e.g. BMI, blood lipids) on PAI-1act and
CLT and whether these interactions were influenced by urban-
isation which can be viewed as a specific combination/grouping of
environmental factors.
Methods
Study population
Participants were recruited to take part in the South African
arm of the international PURE study. This is a large-scale cohort
study that tracks changing lifestyles, risk factors and chronic
disease, using periodic standardised data collection in rural and
urban areas of 17 countries in transition over 12 years [28,29].
The data reported here are from the baseline data of 2010
randomly selected participants from well-established rural and
urban study sites in the North West Province of South Africa,
collected over a twelve-week period in 2005. Details regarding the
selection process and randomisation are reported elsewhere
[10,17]. In short, apparently healthy black South African men
and women between the ages of 35 and 65 years were eligible to
participate. Use of chronic medication for non-communicable
diseases and/or any self-reported acute illness were bases for
exclusion. Equal numbers of rural and urban participants were
included.
Ethics statement
The Ethics Committee of the North-West University, South
Africa, approved this study. The study procedure was explained to
participants in their home language, after which participants
signed informed consent forms and the study commenced. All data
were treated confidentially and all analyses were performed with
coded data.
Blood collection and laboratory analysis
Fasting blood samples were collected between 08:00 and 11:00.
For the analysis of the lipid profile, blood was collected in tubes
without anticoagulant - in EDTA tubes for the determination of
glycosylated haemoglobin (HbA1c) and total homocysteine, and in
fluoride tubes for glucose determination. For the determination of
PAI-1act, fibrinogen concentration, fibrinogen gamma prime,
plasma fibrinolytic potential and for DNA isolation, blood was
collected in citrate tubes. Samples were centrifuged at 20006g for
15 minutes at 10uC within 30 minutes of collection. Aliquots were
frozen on dry ice, stored in the field at 218uC and then, after 2–4
days, at 282uC until analysis.
Methods for the measurement of fibrinogen, lipids, HbA1c,
total homocysteine and plasma glucose have been described
previously [17]. PAI-1act was measured using an indirect
enzymatic method (Spectrolyze PAI-1, Trinity Biotech, Bray,
Ireland). A modified Clauss method (Multifibrin U-test, Dade
Behring, Deerfield, IL, USA) on the Dade Behring BCS
coagulation analyser was used to determine fibrinogen concentra-
tions. Fibrinogen gamma prime was determined with an enzyme-
linked immunosorbent assay (ELISA) method using a 2.G2.H9
mouse monoclonal coating antibody against the human gamma
prime sequence from Santa Cruz Biotechnology (Santa Cruz,
USA) for antigen capture and a goat polyclonal HRP-conjugated
antibody against human fibrinogen from Abcam for development
(Antibody 7539, Cambridge, USA) [30]. Plasma fibrinolytic
potential using tissue-factor-induced plasma clots, lysed by
exogenous tPA, was measured using the method of Lisman et al.
[8], validated by Talens et al. [31] with slightly modified tissue
factor and tPA concentrations in order to obtain comparable
CLTs of about 60 min (intra-assay CV = 3.6%, between plate
CV = 4.5%). Final concentrations were tissue factor (1256diluted
– an estimated final concentration of 59 pM [32]; Dade Innovin,
Siemens Healthcare Diagnostics Inc., Marburg, Germany), CaCl2
(17 mmol/l), tPA (100 ng/ml; Actilyse, Boehringer Ingelheim,
Ingelheim, Germany) and phospholipid vesicles (10 mmol/l;
Rossix, Mo¨lndal, Sweden). CLT was defined as the time from
the midpoint of the transition of clear to maximum turbidity,
which is representative of clot formation, to the midpoint in
transition from maximum turbidity to clear, which represents the
lysis of the clot [8]. CLT and PAI-1act could be determined for
only 1802 and 1913 participants respectively, owing to inadequate
sample volume and/or haemolysis of some samples. Baseline
characteristics of these participants did not differ from those of the
total group.
PAI-1 promoter area sequencing and genotyping
Three overlapping fragments covering the promoter area from
nucleotide position 100 768 248–100 770 521 (according to the
NCBI database NP_000593.1) were sequenced in a subgroup of
25 randomly chosen participants and used as a representative
group of the study population. PCR products were purified and bi-
directionally sequenced using the BigDyeHTerminator v3.1Cycle
Sequencing kit (AppliedBiosystems, CA, USA) (Table S1). After
this, capillary electrophoresis was performed by the Central
Analytical Facility of the Stellenbosch University on a 3130xl
GeneticAnalyser (AppliedBiosystems) [33].
Sequences were aligned to a reference sequence
(NT_007933.15) using BioEdit v7 and were manually checked
for known and novel polymorphisms. Seventeen polymorphisms
were observed (Table S2). After linkage disequilibrium analysis
and exclusion of two SNPs in linkage with the 4G/5G
polymorphism, the polymorphisms with the highest frequencies,
the 4G/5G polymorphism (rs1799889), located at chromosome
position 100769710, and two SNPs located next to each other, at
chromosome position 100768428 and 100768429 (rs36228614)
were selected for analysis in the total PURE population. The novel
polymorphism at position 100768428 will be referred to as
C428T, and the polymorphism next to it as G429A. This SNP has
been previously reported, but no data exists in the literature for
this SNP. The 25 participants from the subgroup were used as
controls in further analysis.
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PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e83151
The 4G/5G-polymorphism was genotyped using TaqMan-
based assays, as previously described [34], using the Biorad IQ5
real-time polymerase chain reaction (PCR) machine (Bio-Rad,
Hercules, USA). A final concentration of 1.2 mM of each primer
was used and 0.4 mM of each probe at an annealing temperature
of 63uC.
The double nucleotide polymorphism C428T-G429A was
genotyped by using a TaqMan-based assay using the BioRad
IQ5 real-time PCR machine. A multiplex real-time PCR reaction
was then performed, using four different probes (Table S3). A final
concentration of 0.4 mM of each primer and 0.2 mM of each probe
was used. The annealing temperature for the reaction was
optimised at 62.4uC. Sequences are available in Table S3.
Statistical analysis
Data were analysed with the computer software package
Statistica (Statsoft Inc., Tulsa Oklahoma, USA). A p-value of
0.05 or less was regarded as statistically significant. Normally
distributed data are reported as means (95% confidence interval or
standard deviation). Data that were not normally distributed were
log-transformed to improve normality and are reported as
geometric mean (95% confidence interval). Owing to the large
number of participants who had PAI-1act values of 0 as calculated
from the standard curve of the assay, a value of 1 was added to all
PAI-1act values before log transformation. This was subtracted
again when reporting the data. Forward stepwise multiple
regression was used to determine the contribution of various
traditional CVD risk factors to PAI-1act variance. Mean differ-
ences with 95%CI and t-tests were used when comparing
differences between two groups. One-way analysis of variance
(ANOVA) and Tukey’s Honest Significant Difference post-hoc
tests were used when comparing more than two groups. To
investigate possible gene-environment interactions between PAI-1
genotypes and other factors and whether these interactions
differed for rural and urban groups, interaction terms were
entered into an analysis of co-variance (ANCOVA) with full
factorial analysis. In addition, regression slopes were compared.
For these interaction analyses, if sample sizes were too small, the
homozygous mutant genotype groups were combined with the
heterozygous group, i.e. 5G/5G compared with the 4G/X allele
group, CC compared with the T/X group, and GG compared
with the A/X group. Analyses of the C428T and G429A SNPs
combined did not yield different results from when analysed
separately (data not reported).
Results
PAI-1act and CLT across PAI-1 genotypes
General population characteristics of the South African PURE
population have been described previously [10,17] and are
included in Table S4. The distribution of all three genotype
classes of each of the polymorphisms investigated adhered to the
assumptions of Hardy Weinberg equilibrium. For the three
polymorphisms we investigated, the linkage disequilibrium in the
total study population between polymorphisms 4G/5G and
C428T was: D’ 1.0, r2 = 0.007; between 4G/5G and G429A D’
0.72, r2 = 0.011; and between C428T and G429A D’ 0.72,
r2 = 0.003. Because of the low r2, we report results for the three
SNPs separately. The allele frequencies of the three polymor-
phisms are presented in Table 1.
The geometric mean PAI-1act level of the South African PURE
population was 3.5561.60 (median 4.26 (1.27–7.92)) U/ml. Data
for PAI-1act levels and CLT across genotypes are presented for the
total population as well as for the urban and rural participants
separately in Table 1. PAI-1act levels for the total population and
for the urban subgroup differed significantly across the 4G/5G
genotypes, where 5G homozygous participants presented with the
lowest PAI-1act levels and 4G homozygous participants with the
highest PAI-1act levels, while heterozygous participants had
intermediate PAI-1act levels. In the rural group, PAI-1act was
higher in the 4G/4G group only. BMI, however, differed across
genotypes in the rural group (5G/5G: 22.6, 4G/5G: 21.3 and 4G/
4G: 25.1 kg/m2 p = 0.008), but not in the urban group (5G/5G:
23.4, 4G/5G: 23.3 and 4G/4G: 25.5 kg/m2 p = 0.83). Because of
the known relationship between BMI and PAI-1 levels, we
adjusted for BMI. After this adjustment, differences between PAI-
1act levels across the genotypes remained in the urban subgroup
but had only borderline significance in the rural group (p = 0.06).
No significant differences in clot lysis times between the genotype
subclasses of the 4G/5G polymorphism were detected in the total
population (p = 0.12) or in the urban group (p = 0.40). However, in
the rural participants, those who had the homozygous 4G
genotype had borderline significantly longer CLT than the
homozygous 5G and heterozygous genotypes (63.1 vs 57.0 and
56.6 minutes, p = 0.04). Again after the adjustment for BMI, this
significance disappeared.
Because the homozygous mutant genotype group (TT) of
C428T was too small (n = 2) to include in further analysis as a
separate group, it was combined with the CT heterozygous group.
Neither PAI-1act levels nor clot lysis times differed significantly
between the homozygous C or T-allele group of C428T for the
total population or for the rural and urban subgroups.
For the G429A SNP, the homozygous mutant (AA genotype)
(n = 27) was also combined with the GA genotype for further
analysis. No significant differences in PAI-1act levels or clot lysis
times were observed between the GG and A-allele genotypes in the
total, rural or urban groups, except for PAI-1act, which was higher
in the GG-genotype than in the group carrying the A-allele in the
urban subgroup.
Associations of cardiovascular disease risk factors with
PAI-1act
The contributions of various traditional CVD risk factors to
PAI-1act variance in this population were determined using
forward stepwise multiple regression. Risk factors included in the
regression model were: age, sex, waist circumference, triglycerides,
HDL-cholesterol, LDL-cholesterol, HbA1c, total homocysteine,
fibrinogen, fibrinogen gamma prime, blood pressure, smoking and
4G/5G genotype. These factors explained 24% of the variance in
PAI-1act in this population. Waist circumference explained most of
the variance with 12.5%, sex, triglyceride and fibrinogen
concentration explained 5%, 4% and 1% respectively, while the
4G/5G polymorphism, fibrinogen gamma prime, blood pressure,
smoking and HDL-cholesterol each explained less than 1%. Age,
LDL-cholesterol, HbA1c and tHcy did not enter the model.
Associations of CLT and CVD risk factors have been reported in
De Lange et al. [10].
Gene-environment interactions
Next we investigated the possibility of gene-environment
interactions on PAI-1act levels and CLT using the CVD risk
factors that were significantly associated with PAI-1 and CLT.
Results are presented for the interactions found for the 4G/5G
polymorphism with PAI-1act and CLT. Results reporting interac-
tions of the C428T and G429A polymorphisms with PAI-1act and
CLT are available in Supporting Information S1 and Table S5.
When the participants were divided according to BMI, PAI-1act
differed across the genotypes of the 4G/5G polymorphism in
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individuals in the normal, overweight and obese BMI range, but
not in underweight participants (BMI ,18.5 kg.m2), and in
participants with central adiposity but not in participants with
normal waist circumferences (Table 2). CLT did not differ across
the genotypes in any of the BMI categories, but tended to be
longer in the 4G allele carriers in participants with central obesity.
Distribution of the 4G/5G genotypes were similar in individuals
with a BMI of,25 kg/m2 and individuals with a BMI of.25 kg/
m2 (BMI ,25 kg/m2: 5G/5G 73%; 4G/5G 25%; 4G/4G/ 2%:
BMI .25 kg/m2: 5G/5G 73%; 4G/5G 23%; 4G/4G/ 3.7%).
Furthermore, there was no difference in genotype distribution
between individuals with abdominal obesity and those with normal
waist circumference (abdominal obesity: 5G/5G 70%; 4G/5G
26%; 4G/4G/ 4%: normal waist circumference: 5G/5G 73%;
4G/5G 24%; 4G/4G/ 2.3%). There was also no difference in
BMI and waist circumference (WC) across the 4G/5G genotypes
(data not shown) in the total study population.
The 4G/5G polymorphism had significant interactions with
WC (p = 0.001), BMI (p = 0.006) and triglyceride concentration
(p = 0.04) in determining PAI-1act (Table 3). In participants with
the 4G allele, there was a greater increase in PAI-1act with an
increase in WC, BMI and triglycerides than in 5G/5G homozy-
gotes. The 4G/5G polymorphism had significant interactions with
fibrinogen (p = 0.005) and fibrinogen gamma prime (p = 0.04)
concentration in determining CLT (Table 3). In participants with
the 4G allele, there was a greater increase in CLT with an increase
in fibrinogen and fibrinogen gamma prime concentration than in
5G/5G homozygotes. Urbanisation did not influence these gene-
environment interactions.
The genotypes of the C428T and G429A polymorphisms also
had significant interactions with various CVD risk factors in
determining PAI-1act and CLT (Table S5). In general it seems
that, for both polymorphisms, differences in gene-environment
interactions were observed between rural and urban participants
in individuals harbouring the respective mutant alleles, while no
rural-urban differences were present in participants homozygous
for the respective wild type alleles.
Discussion
This study provides the first population-based data for genotype
frequencies of the 4G/5G polymorphism in a large black African
population. To date there have been only three small-scale studies
and our data indicate an even higher prevalence of the 5G allele
than previously reported for African Americans. In addition we
aimed to identify other factors contributing to PAI-1act variance in
Africans by identifying other polymorphisms in the PAI-1
promoter area and determining their relation to PAI-1act levels
and CLT. Lastly we demonstrated that gene-environment
interactions between the three investigated polymorphisms and
several traditional CVD risk factors significantly affected PAI-1act
and CLT, and that level of urbanisation (rural or urban),
representing two different sets of specific combinations of
environmental factors, significantly influenced phenotypic expres-
sion of these polymorphisms.
Table 1. PAI-1act levels and clot lysis time of PAI-1 promoter area polymorphisms.
Polymorphism
Allele
Freq. N (%) PAI-1act (U/ml) CLT (min)
Total group Urban Rural Total group Urban Rural
4G/5G: 5G/5G 5G: 0.85 1304 (72.5) 3.35 (3.13-3.58)* 3.93 (3.56–4.32)*{ 2.90 (2.64-3.18)* 57.0 (56.4-57.6) 57.1 (56.1-58.1) 57.0 (56.2-57.8)*
(n = 1302) (n = 602) (n = 700) (n = 1223) (n = 557) (n = 666)
4G/5G 448 (24.9) 3.90 (3.48-4.37)* 4.87 (4.20-5.64)* 2.95 (2.47-3.50){ 57.5 (56.4-58.6) 58.3 (56.7-59.9) 56.6 (55.1-58.1){
(n = 446) (n = 243) (n = 203) (n = 426) (n = 229) (n = 197)
4G/4G 4G: 0.15 47 (2.61) 5.87 (4.10-8.25)* 5.97 (3.45-9.92){ 5.74 (3.3.46-9.18)*{ 60.5 (55.8-65.2) 58.5 (51.6-65.4) 63.1 (56.3-69.8)*{
(n = 47) (n = 26) (n = 21) (n = 43) (n = 24) (n = 19)
ANOVA p-value p,0.001 p = 0.02 p = 0.03 p = 0.12 p = 0.40 p = 0.04
ANCOVA p-value# (p = 0.0003) (p = 0.009) (p = 0.06) (p = 0.15) (p = 0.39) (p = 0.12)
C428T: CC C: 0.96 1743 (92.3) 3.59 (3.39-3.80) 4.25 (3.82-4.60) 3.02 (2.78-3.28) 57.3 (56.7-57.8) 57.5 (56.7-58.3) 57.1 (56.3-57.8)
(n = 1739) (n = 861) (n = 878) (n = 1640) (n = 801) (n = 839)
CT/TT T: 0.04 145 (7.7) 3.06 (2.48-3.73) 4.05 (2.98-5.40) 2.44 (1.83-3.18) 57.4 (55.6-59.2) 58.0 (54.8-61.3) 56.9 (54.8-59.0)
(n = 144) (n = 62) (n = 82) (n = 136) (n = 57) (n = 79)
ANOVA p-value p = 0.14N p =0.75N p= 0.15N p =0.92N p= 0.74N p=0.90N
G429A: GG G: 0.90 1528 (80.9) 3.61 (3.40-3.84) 4.43 (4.07-4.81) 2.92 (2.67-3.19) 57.3 (56.7-57.9) 57.6 (56.7-58.4) 57.0 (56.2-57.8)
(n = 1524) (n = 760) (n = 764) (n = 1443) (n = 713) (n = 730)
GA /AA A: 0.10 360 (19.1) 3.28 (2.88-3.72) 3.44 (2.81-4.17) 3.15 (2.66-3.71) 57.3 (56.1-58.4) 57.4 (55.4-59.3) 57.2 (55.7-58.6)
(n = 359) (n = 163) (n = 196) (n = 333) (n = 145) (n = 188)
ANOVA p-value p = 0.18N p =0.02N p= 0.45N p =0.97N p= 0.86N p=0.85N
PAI-1act data reported as geometric means (95% CI), normally distributed data (CLT) reported as mean (95% CI). PAI-1act: Plasminogen activator inhibitor type-1 activity;
CLT: clot lysis time.
*{Values with the same symbol differed significantly between genotypes for the total, urban and rural groups respectively.
#p-values after adjustment for BMI;
Np-value reported for CC vs CT and TT groups combined for C428T, and GG vs GA and AA groups combined for G429A because of small sample size in homozygous
mutant groups.
doi:10.1371/journal.pone.0083151.t001
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PAI-1act and CLT across PAI-1 genotypes
In this large black African population we found a high
prevalence of the 5G/5G genotype (72.5%) of the 4G/5G
polymorphism. These results agree with the results of two small-
scale studies conducted in black South African participants, in
which the 5G homozygous genotype was present in 76% and
77.6% of the populations in comparison with 36% and 19.3% in
white South Africans [15,26]. The 5G allele frequency (0.85) was
higher than that reported for African American, (0.74 and 0.72),
and white populations (0.38 and 0.28) [12,25].
In agreement with results from other studies, we also found PAI-
1act levels of the 4G homozygous genotype to be higher than those
of the 4G/5G heterozygous and 5G homozygous genotypes, with
the 4G/5G genotype group presenting with intermediate PAI-1act
levels in the overall population [12,22,23]. Interestingly, this
difference in PAI-1act levels between genotypes of the 4G/5G
polymorphism was much more pronounced in the urban than in
the rural subgroup, suggesting that urbanisation-dependent stimuli
might modulate gene expression through an interaction with the
4G/5G polymorphism. Future studies identifying these stimuli are
warranted to confirm this hypothesis. Despite increased PAI-1act
levels in both the rural and urban subgroups in the 4G/4G
genotype, this change did not translate to longer CLTs.
Neither PAI-1act nor CLT differed across the novel C428T or
the G429A genotype except in the urban subgroup, where
homozygous wildtype participants had significantly higher PAI-
1act levels than the A-allele group. Although the G429A
polymorphism has been previously identified, no information is
available in the literature regarding its effect on PAI-1 levels. A
possible reason for the apparent lack of effect of these two SNPs
may be that the SNPs were not present within a known
transcription factor binding site (as determined with the UCSC
genome browser using the TFBS conserved and ENCODE
regulation tracks).
Associations of cardiovascular disease risk factors with
PAI-1act
The 4G/5G polymorphism explained less than one percent of
the variance of PAI-1act in this population. The main contributor
to PAI-1act variance in this population was waist circumference,
followed by sex and triglyceride concentration. This is in
agreement with Verschuur et al. [35], who found obesity to be a
more important determinant of PAI-1 levels than genetic variation
in the PAI-1 promoter area. It is also possible, however, that PAI-1
levels can be influenced by polymorphisms outside the PAI-1 gene.
Huang et al. [21], for example recently found SNPs in the ARNTL
and the PPARG genes to have genome-wide significant association
with circulating PAI-1 levels.
Table 2. PAI-1act and CLT across BMI and waist circumference categories for 5G/5G participants and those harbouring the 4G
genotype
PAI-1act (U/ml) CLT (minutes)
N 5G/5G 4G-allele
Mean difference
(95% CI) 5G/5G 4G-allele
Mean difference
(95% CI)
Mean* (95% CI) Mean* (95% CI) Mean (95% CI) Mean (95% CI)
BMI (kg/m2): ,18.5 319 1.89 (1.56-2.26) 1.64 (1.18-2.21) 0.24 (-0.14-0.62) 50.7 (49.2-52.2) 50.9 (48.6-53.2) 0.24 (-2.48-2.95)
18.5-24.9 731 2.65 (2.37-2.94) 3.59 (3.03-4.22) 0.94 (0.69-1.18) 54.9 (54.0-55.8) 56.1 (54.5-57.7) 1.22 (-0.59-3.02)
25-29.9 298 4.83 (4.23-5.49) 6.22 (4.95-7.75) 1.39 (1.05-1.74) 60.7 (59.4-61.9) 61.6 (58.8-64.4) 0.92 (-2.11-3.95)
$30 353 5.52 (4.87-6.25) 7.55 (6.12-9.28) 2.03 (1.69-2.37) 64.2 (63.1-65.3) 65.1 (63.0-67.3) 0.91 (-1.52-3.33)
Waist circumference: Normal WC 1422 2.89 (2.67-3.12) 3.14 (2.76-3.55) 0.25 (-0.07-0.43) 55.3 (54.6-56.0) 55.3 (54.2-56.5) 0.06 (-1.24-1.36)
Centrally obese 356 5.59 (5.22-6.62) 9.29 (7.78-11.1) 3.41 (3.12-3.70) 64.4 (63.3-65.5) 66.7 (64.3-69.2) 2.33 (-0.33-4.99)
*Geometric mean; PAI-1act: Plasminogen activator inhibitor type-1 activity; CLT: clot lysis time; BMI: Body mass index; WC: Waist circumference; Normal WC: ,80cm for
women and ,94cm for men; Central obesity, $80cm for women and $94cm for men.
doi:10.1371/journal.pone.0083151.t002
Table 3. PAI-1act: plasminogen activator inhibitor-1 activity; BMI: body mass index; CLT: clot lysis time.
5G/5G 4G allele
Interaction
Interaction p-
value* N Slope (95% CI) N Slope (95% CI)
PAI-1act: Waist circumference (cm) 0.001 1289 1.89 (1.57; 2.21) 489 2.92 (2.42; 3.43)
BMI (kg/m2) 0.006 1241 1.15 (0.96; 1.34) 460 1.66 (1.35; 1.97)
Triglycerides (mmol/l) 0.04 1259 0.56 (0.46; 0.66) 481 0.78 (0.60; 0.95)
CLT: Fibrinogen (g/L) 0.005 1149 2.69 (1.55; 3.82) 425 5.94 (3.83; 8.06)
Fibrinogen gamma prime (g/L) 0.04 1173 6.78 (5.69; 7.88) 444 9.04 (7.06; 11.0)
PAI-1act: plasminogen activator inhibitor-1 activity; BMI: body mass index; CLT: clot lysis time.
N Slope: regression line obtained by plotting PAI-1act or CLT (y-axis) against environmental factors (x-axis).
*p-values indicate significance of the interaction term of the 4G/5G genotype and environmental factor in an ANCOVA.
doi:10.1371/journal.pone.0083151.t003
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Gene-environment interactions - 4G/5G polymorphism
The relationship between PAI-1 levels, the 4G/5G genotype
and BMI, although extensively studied, remains controversial.
Genotype-specific differences in PAI-1act levels were present in all
BMI ranges in our study population, except for BMI ,18.8 kg/
m2, whereas in white populations, they have sometimes been
observed in obese individuals only [36–38], while in other studies
[35] they have appeared in lean individuals only. In agreement
with results from Sartori et al. [38], these differences were also
present in individuals with central obesity but not in those with a
normal waist circumference. We additionally found significant
interactions of the 4G/5G genotypes with waist circumference and
BMI in determining PAI-1act levels in this apparently healthy
population, with PAI-1act increasing more rapidly with increasing
BMI and WC in the 4G allele group. These results are in
agreement with McCormack et al. [39], who investigated these
associations in Pima Indians. Ossei-Gerning et al. [23], however,
found the association between BMI and PAI-1 to be stronger in
the 5G/5G genotype in a group of 453 white patients with a
history of myocardial infarction. In vitro studies aiming at
elucidating possible mechanisms for this interaction, found no
effect of genotype on promoter activity in HepG2 or BEAC cells
[35], nor did it influence the adipose secretion rate of PAI-1 [40].
With the 4G/5G polymorphism being a response polymorphism,
ethnic differences as well as differences in study population
characteristics (healthy vs diseased), probably contribute to these
discrepancies in the literature.
The relationship between PAI-1act and triglyceride levels was
also found to be influenced by the 4G/5G genotype in our study
population, with PAI-1act increasing more rapidly with increasing
triglycerides in the 4G allele group. Similar associations were
found in studies investigating CVD patients [23,41,42], although
in studies investigating healthy white individuals, genotype was not
found to influence this relationship [22,43]. A possible explanation
for the observed 4G/5G–triglyceride interaction is that the activity
of a VLDL-response element in the PAI-1 promoter area was
found to be influenced by the 4G/5G polymorphism located
adjacent to and upstream of the binding site of the VLDL-
inducible transcription factor [44].
As yet, it is still unclear whether PAI-1 plays a role in the
evolution of obesity and whether the 4G/5G polymorphism could
possibly contribute to this. While some case-control studies found
differences in genotype distribution between obese and non-obese
participants [45,46], others did not [38]. Our data, providing the
first population-based evidence, indicated that there were no
differences in genotype distribution between individuals of normal
weight and those who were overweight/obese. Additionally, BMI
and WC did not differ across the genotypes. This is in agreement
with Gardemann et al. [47] but in contradiction to Hoffsted et al.
[45], who found the prevalence of obesity to be twice as high in the
4G allele as in the 5G allele group. In an in vitro experiment,
Demiralp et al. [48] suggest that overexpression of PAI-1 in 3T3-
L1 cells can increase adipocyte differentiation and that the 4G
allele was significantly more active than the 5G allele in driving
PAI-1 gene transcription, in this way contributing to adipogenesis.
More evidence from population-based studies, comparing different
ethnicities is required, however, to determine the role of PAI-1 and
its gene regulation in obesity. Genome wide association studies
(GWAS) have shown that various genes influence obesity [49,50],
but, to our knowledge no GWAS have been published investigat-
ing the influence of the polymorphisms we investigated and their
associations with obesity.
We found significant interactions of the 4G/5G genotypes with
fibrinogen and fibrinogen gamma prime in determining CLT.
Fibrinogen gamma prime was included in this investigation as it
has been shown to affect clot structure, which may influence lysis
[51]. In participants with the 4G allele, there was a greater
increase in clot lysis time with an increase in fibrinogen and
fibrinogen gamma prime than in 5G/5G homozygotes. Olman et
al. [52] identified an AP-1-like DNA element as important in
transcriptional control in the PAI-1 gene. According to Olman et
al. [52], a negative regulatory feedback loop is initiated, wherein
D-dimers, formed after fibrin degradation, generate a signal that
results in PAI-1 transcription through the AP-1 expression
element, inhibiting fibrinolysis. The influence of increasing
fibrinogen and fibrinogen gamma prime concentrations on clot
lysis in the present study may, therefore, amongst other reasons, be
through the increased generation of D-dimer. If the AP-1
expression element enhances PAI-1 mRNA in the 4G but not
the 5G allele, as has been demonstrated for interleukin-1 [18] and
VLDL, it could at least in part explain the observed gene-
environment interactions. The enhanced transcription of PAI-1
could consequently result in prolonged CLT. Additional research
is required, however, to test this hypothesis.
C428T and G429A polymorphisms
Despite there being no direct relationship between these
polymorphisms and PAI-1act and CLT, we did find evidence that
the association of other environmental factors with PAI-1act and
CLT was influenced by these genotypes. Additionally, many, but
not all, of the gene-environment interactions differed consistently
between rural and urban participants in subjects harbouring the
mutant alleles, but not in subjects harbouring the most common
genotype. These data suggest that significant differences in
environmental factors in urban and rural living conditions could
potentially influence phenotypic expression of the investigated
SNPs in subjects harbouring the mutant variants and that these
individuals may be more sensitive towards environmental factors
than individuals harbouring the respective common genotypes.
In conclusion, this black African population had a high
prevalence of the 5G allele (0.85). The 4G/5G polymorphism
significantly affected PAI-1act but not CLT. The polymorphism
contributed, however, to less than 1% in the PAI-1act variance.
Obesity had a much more pronounced effect on PAI-1act than the
measured polymorphisms. The C428T and G429A SNPs had no
direct association with either PAI-1act or CLT. There were
significant gene-environment interactions for all three polymor-
phism investigated in determining PAI-1act and CLT. Urbanisa-
tion significantly affected the phenotypic expression of the 4G/5G
polymorphism, with PAI-1act showing larger differences across the
4G/5G genotypes in the urban community than in the rural
community. Urbanisation additionally influenced gene-environ-
ment interactions, with differences between rural and urban
participants observed particularly in participants harbouring the
minor alleles of the C428T and G429 polymorphisms. From these
results it seems clear that environmental factors and combinations
thereof, such as specific combinations present in a rural or urban
environment, significantly influence phenotypic expression of
genes. This should be taken into consideration when developing
treatment modalities addressing CVD risk factors such as PAI-1
and hypofibrinolysis in communities in transition.
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